Cardiovascular and renal outcomes with empagliflozin in heart failure

New England Journal of Medicine

Volumn 383, Issue 15, 2020, Pages 1413-1424

  Packer, Milton ^a,b   Anker, Stefan D ^f   Butler, Javed ^k   Filippatos, Gerasimos ^l   Pocock, Stuart J ^c   Carson, Peter ^m   Januzzi, James ⁿ   Verma, Subodh ^o   Tsutsui, Hiroyuki ^r   Brueckmann, Martina ^g,h   Jamal, Waheed ^g   Kimura, Karen ^p   Schnee, Janet ^s   Zeller, Cordula ^g   Cotton, Daniel ^s   Bocchi, Edimar ^t   Bohm, Michael ⁱ   Choi, Dong‑Ju ^u   Chopra, Vijay ^v   Chuquiure, Eduardo ^w   Giannetti, Nadia ^q   Janssens, Stefan ^x   Zhang, Jian ^y   Gonzalez Juanatey, Jose R ^z   Kaul, Sanjay ^aa   Brunner‑La Rocca, Hans‑Peter ^ab   Merkely, Bela ^ac   Nicholls, Stephen J ^ad   Perrone, Sergio ^ae   Pina, Ileana ^af   Ponikowski, Piotr ^ag   Sattar, Naveed ^d   Senni, Michele ^ah   Seronde, Marie‑France ^aj   Spinar, Jindrich ^al   Squire, Iain ^e   Taddei, Stefano ^ai   Wanner, Christoph ^j   Zannad, Faiez ^ak   more..

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c The Department of Medical Statistics   (United Kingdom)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e UNIVERSITY OF LEICESTER   (United Kingdom)

^f BERLIN INSTITUTE OF HEALTH   (Germany)

^g BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^h UNIVERSITY OF HEIDELBERG   (Germany)

ⁱ SAARLAND UNIVERSITY   (Germany)

^j UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^k UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^l UNIVERSITY OF ATHENS   (Greece)

^m VETERANS AFFAIRS MEDICAL CENTER   (United States)

ⁿ MASSACHUSETTS GENERAL HOSPITAL   (United States)

^o ST MICHAEL'S HOSPITAL   (Canada)

^p BOEHRINGER INGELHEIM CANADA LTD   (Canada)

^q MCGILL UNIVERSITY   (Canada)

^r KYUSHU UNIVERSITY   (Japan)

^s BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^t UNIVERSITY OF SÃO PAULO   (Brazil)

^u Seoul National University   (South Korea)

^v Max Super Speciality Hospital   (India)

^w INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

^x UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^y FUWAI HOSPITAL   (China)

^z Instituto de Salud Carlos III   (Spain)

^aa CEDARS SINAI MEDICAL CENTER   (United States)

^ab MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^ac SEMMELWEIS UNIVERSITY   (Hungary)

^ad MONASH UNIVERSITY   (Australia)

^ae FLENI   (Argentina)

^af WAYNE STATE UNIVERSITY   (United States)

^ag WROCLAW MEDICAL UNIVERSITY   (Poland)

^ah PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^ai UNIVERSITY OF PISA   (Italy)

^aj UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^ak UNIVERSITÉ DE LORRAINE   (France)

^al UNIVERSITY HOSPITAL BRNO   (Czech Republic)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; EMPAGLIFLOZIN; PLACEBO; BENZHYDRYL DERIVATIVE; GLUCOSIDE;

AGED; ARTICLE; BODY SURFACE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CLINICAL OUTCOME; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; GENITAL TRACT INFECTION; HEART; HEART EJECTION FRACTION; HEART FAILURE; HOSPITALIZATION; HUMAN; KIDNEY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT SAFETY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; ADVERSE EVENT; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COMPLICATION; DRUG EFFECT; GLOMERULUS FILTRATION RATE; HEART STROKE VOLUME; MIDDLE AGED; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL;

AGED; BENZHYDRYL COMPOUNDS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; GLOMERULAR FILTRATION RATE; GLUCOSIDES; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RENAL INSUFFICIENCY, CHRONIC; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; STROKE VOLUME;

EID: 85090992310     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa2022190     Document Type: Article

References (10)

1. Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019;393:31-9.
2. Kato ET, Silverman MG, Mosenzon O, et al. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation 2019;139:2528-36.
3. Packer M. SGLT2 inhibitors produce cardiorenal benefits by promoting adaptive cellular reprogramming to induce a state of fasting mimicry: a paradigm shift in understanding their mechanism of action. Diabetes Care 2020;43:508-11.
4. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019;381:1995-2008.
5. Packer M, Butler J, Filippatos GS, et al. Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial. Eur J Heart Fail 2019;21:1270-8.
6. Ibrahim NE, Burnett JC Jr, Butler J, et al. Natriuretic peptides as inclusion criteria in clinical trials: a JACC heart failure position paper. JACC Heart Fail 2020;8: 347-58.
7. Fitchett D, Inzucchi SE, Cannon CP, et al. Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME trial. Circulation 2019;139:1384-95.
8. Furtado RHM, Bonaca MP, Raz I, et al. Dapagliflozin and cardiovascular outcomes in patients with type 2 diabetes mellitus and previous myocardial infarction. Circulation 2019;139:2516-27.
9. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:644-57.
10. Donnan JR, Grandy CA, Chibrikov E, et al. Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis. BMJ Open 2019;9(1):e022577.